Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases

por Abdelmagid, Maymona G., Litzow, Mark R., McCullough, Kristen B., Gangat, Naseema, Pardanani, Animesh, Murthy, Hemant S., Foran, James M., Ketterling, Rhett P., Viswanatha, David, Begna, Kebede H., Tefferi, Ayalew
Publicado 2022

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival

por Abdelmagid, Maymona G., Al-Kali, Aref, Begna, Kebede H., Hogan, William J., Litzow, Mark R., Fleti, Farah, Mangaonkar, Abhishek A., Patnaik, Mrinal S., Elliott, Michelle A., Alkhateeb, Hassan, Shi, Min, Howard, Matthew T., Reichard, Kaaren K., Ketterling, Rhett P., Shah, Mithun, Pardanani, Animesh, Gangat, Naseema, Tefferi, Ayalew
Publicado 2023

Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusiv...

por Abdelmagid, Maymona G., Al-Kali, Aref, Litzow, Mark R., Begna, Kebede H., Hogan, William J., Patnaik, Mirinal S., Hashmi, Shahrukh K., Elliott, Michelle A., Alkhateeb, Hassan, Karrar, Omer S., Fleti, Farah, Elnayir, Mohammed H., Rivera, Candido E., Murthy, Hemant S., Foran, James M., Kharfan-Dabaja, Mohamed A., Badar, Talha, Viswanatha, David S., Reichard, Kaaren K., Gangat, Naseema, Tefferi, Ayalew
Publicado 2023